Persistent high residual inflammatory risk is associated with an increased major adverse cardiac and cerebrovascular accident risk in patients undergoing percutaneous coronary intervention who have a low baseline low-density lipoprotein level.
The NLA has released updated guidance for clinicians on identifying patients for which PCSK9 inhibitor therapy would provide reasonable value.
The unaffected siblings of patients with bipolar disorder have increased risks for dyslipidemia and ischemic stroke.
Investigators substantiated strategies to encourage approval rates for proprotein convertase subtilisin/kexin type 9 inhibitors.
Investigators sought to determine whether lipoprotein(a) and oxidized phospholipids on apolipoprotein B-100 levels can affect disease activity, disease progression, and clinical events in patients with aortic stenosis.
Investigators used Mendelian randomization analysis to determine the amount of lipoprotein(a) reduction needed to match the effect on coronary heart disease outcomes that lowering low-density lipoprotein cholesterol has.
Researchers identified 2 lipid ratios that were useful markers for metabolic syndrome in adolescents with central adiposity.
An HDL apolipoproteomic score was associated with the presence of coronary artery disease, independent of other conventional cardiovascular risk factors.
A weighted cardiometabolic disease staging risk score can be used to quantify race- and sex-specific type 2 diabetes risk in a large, diverse population.
Treatment with linagliptin in patients with type 2 diabetes and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events.
